BR0112788A - Receptores para fatores de diferenciação de crescimento, agonistas e antagonistas dos mesmos e processos de utilização desses - Google Patents
Receptores para fatores de diferenciação de crescimento, agonistas e antagonistas dos mesmos e processos de utilização dessesInfo
- Publication number
- BR0112788A BR0112788A BR0112788-8A BR0112788A BR0112788A BR 0112788 A BR0112788 A BR 0112788A BR 0112788 A BR0112788 A BR 0112788A BR 0112788 A BR0112788 A BR 0112788A
- Authority
- BR
- Brazil
- Prior art keywords
- myostatin
- cell
- provides
- modulating
- gdf
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 102000014015 Growth Differentiation Factors Human genes 0.000 title abstract 2
- 108010050777 Growth Differentiation Factors Proteins 0.000 title abstract 2
- 239000000556 agonist Substances 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title abstract 2
- 102000004472 Myostatin Human genes 0.000 abstract 6
- 108010056852 Myostatin Proteins 0.000 abstract 6
- 210000004027 cell Anatomy 0.000 abstract 4
- 210000000577 adipose tissue Anatomy 0.000 abstract 3
- 230000019491 signal transduction Effects 0.000 abstract 3
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 210000003205 muscle Anatomy 0.000 abstract 2
- 230000001717 pathogenic effect Effects 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 230000002159 abnormal effect Effects 0.000 abstract 1
- 230000003247 decreasing effect Effects 0.000 abstract 1
- 230000004069 differentiation Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 210000000663 muscle cell Anatomy 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0271—Chimeric vertebrates, e.g. comprising exogenous cells
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/0306—Animal model for genetic diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Environmental Sciences (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- Wood Science & Technology (AREA)
- Urology & Nephrology (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Neurology (AREA)
Abstract
"RECEPTORES PARA FATORES DE DIFERENCIAçãO DE CRESCIMENTO, AGONISTAS E ANTAGONISTAS DOS MESMOS E PROCESSOS DE UTILIZAçãO DESSES". A presente invenção fornece um receptor para um fator de diferenciação de crescimento (GDF) substancialmente purificado, incluindo um receptor para o GDF-8 (mioestatina), assim como porções peptídicas funcionais do mesmo. Em adição, a invenção fornece uma representação virtual de um receptor para GDF ou de uma porção peptídica funcional do mesmo. A presente invenção fornece também um processo para modular um efeito da mioestatina sobre uma célula através do contato da célula com um agente que afeta a transdução de sinal pela mioestatina na célula. Em adição, a invenção fornece um processo para diminuir a gravidade de um estado de saúde patogênico, que é caracterizado, pelo menos em parte, por uma quantidade, desenvolvimento ou atividade metabólica anormal do tecido muscular ou adiposo em um indivíduo, através da modulação da transdução de sinal pela mioestatina em uma célula muscular ou em uma célula do tecido adiposo no indivíduo. A invenção fornece ainda um processo para modular o crescimento do tecido muscular ou do tecido adiposo em um organismo eucariótico através da administração de um agente que afeta a transdução de sinal pela mioestatina ao organismo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/626,896 US6656475B1 (en) | 1997-08-01 | 2000-07-27 | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
PCT/US2001/023615 WO2002010214A2 (en) | 2000-07-27 | 2001-07-26 | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0112788A true BR0112788A (pt) | 2003-09-09 |
Family
ID=24512319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0112788-8A BR0112788A (pt) | 2000-07-27 | 2001-07-26 | Receptores para fatores de diferenciação de crescimento, agonistas e antagonistas dos mesmos e processos de utilização desses |
Country Status (19)
Country | Link |
---|---|
US (1) | US6656475B1 (pt) |
EP (2) | EP1317485B1 (pt) |
JP (2) | JP5153985B2 (pt) |
CN (2) | CN101402955A (pt) |
AR (1) | AR033384A1 (pt) |
AT (1) | ATE503487T1 (pt) |
AU (2) | AU8299901A (pt) |
BR (1) | BR0112788A (pt) |
CA (1) | CA2417568C (pt) |
DE (1) | DE60144334D1 (pt) |
DK (1) | DK1317485T3 (pt) |
ES (2) | ES2364126T3 (pt) |
IL (2) | IL153975A0 (pt) |
MX (1) | MXPA03000787A (pt) |
NZ (2) | NZ523617A (pt) |
PL (1) | PL365792A1 (pt) |
PT (1) | PT1317485E (pt) |
WO (1) | WO2002010214A2 (pt) |
ZA (1) | ZA200300480B (pt) |
Families Citing this family (91)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7393682B1 (en) * | 1993-03-19 | 2008-07-01 | The Johns Hopkins University School Of Medicine | Polynucleotides encoding promyostatin polypeptides |
ES2201076T3 (es) * | 1993-03-19 | 2004-03-16 | The Johns Hopkins University School Of Medicine | Factor-8 de diferenciacion del crecimiento. |
US7566768B1 (en) | 1995-10-26 | 2009-07-28 | The Johns Hopkins University School Of Medicine | Promyostatin peptides and methods of using same |
US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
TWI329129B (en) * | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
US7320789B2 (en) * | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
AU2003216345A1 (en) * | 2002-02-21 | 2003-09-09 | Wyeth | Follistatin domain containing proteins |
BR0307907A2 (pt) * | 2002-02-21 | 2011-07-05 | Wyeth Corp | gasp1: proteìna contendo domìnio de folistatina |
US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
AU2003267246A1 (en) * | 2002-09-16 | 2004-04-30 | The Johns Hopkins University | Metalloprotease activation of myostatin, and methods of modulating myostatin activity |
AR047392A1 (es) * | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
US20040223966A1 (en) * | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
KR20140004805A (ko) | 2002-12-20 | 2014-01-13 | 암겐 인코포레이티드 | 미오스타틴을 저해하는 결합제 |
JP5110877B2 (ja) | 2003-06-02 | 2012-12-26 | ワイス・エルエルシー | 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン(gdf8)インヒビターの使用 |
US7371726B2 (en) | 2003-12-31 | 2008-05-13 | Schering-Plough Animal Health Corporation | Neutralizing GDF8 epitope-based growth enhancing vaccine |
JP4688483B2 (ja) | 2004-04-15 | 2011-05-25 | 株式会社テクノネットワーク四国 | フォリスタチン変異体ポリペプチド |
EP1755648A2 (en) | 2004-05-27 | 2007-02-28 | Acceleron Pharma Inc. | Cerberus/coco derivatives and uses thereof |
US9045553B2 (en) | 2004-05-27 | 2015-06-02 | Acceleron Pharma, Inc. | Cerberus/Coco derivatives and uses thereof |
JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ActRII受容体ポリペプチド、方法、および組成物 |
WO2006025988A1 (en) * | 2004-07-29 | 2006-03-09 | Schering-Plough Ltd. | Use of alk 5 inhibitors to modulate or inhibit myostatin activity leading to increased lean tissue accretion in animals |
AU2005272646A1 (en) * | 2004-08-12 | 2006-02-23 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using GDF-8 inhibitors |
EP1799709B1 (en) * | 2004-09-30 | 2012-04-04 | ORICO Limited | Myostatin isoform |
JP2008000003A (ja) * | 2004-10-01 | 2008-01-10 | Oncorex Inc | Pim−1活性/蛋白阻害医薬品 |
JP2008526201A (ja) * | 2004-12-30 | 2008-07-24 | シェーリング−プラウ・リミテッド | 中和エピトープベースの成長増強ワクチン |
CN101137906A (zh) * | 2005-03-23 | 2008-03-05 | 惠氏公司 | 对gdf-8调节剂的免疫应答的检测 |
GB2441581B (en) * | 2005-06-24 | 2011-01-19 | Roderic M K Dale | Compositions and methods for the treatment of muscle wasting |
CN100393320C (zh) * | 2005-06-24 | 2008-06-11 | 奥林格斯技术有限公司 | 治疗肌肉萎缩的寡核苷酸药物 |
BRPI0616923A2 (pt) * | 2005-10-06 | 2011-07-05 | Lilly Co Eli | anticorpos monoclonais, seus usos e composição farmacêutica |
UA92504C2 (en) * | 2005-10-12 | 2010-11-10 | Эли Лилли Энд Компани | Anti-myostatin monoclonal antibody |
US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
KR20150115961A (ko) * | 2005-11-23 | 2015-10-14 | 악셀레론 파마 인코포레이티드 | 액티빈-actrⅱa 길항제 및 골 성장을 촉진하기 위한 이들의 용도 |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
US20070149458A1 (en) * | 2005-12-06 | 2007-06-28 | Amgen Inc. | Uses of myostatin antagonists |
JP2007306885A (ja) * | 2006-05-22 | 2007-11-29 | Mitsubishi Chemicals Corp | 新規非ヒト動物 |
AU2006345724B2 (en) * | 2006-06-30 | 2013-11-21 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
US8097596B2 (en) * | 2006-06-30 | 2012-01-17 | Lakewood-Amedex, Inc. | Compositions and methods for the treatment of muscle wasting |
WO2008005019A1 (en) * | 2006-07-07 | 2008-01-10 | Dale Roderic M K | Compositions and methods for the treatment of muscle wasting |
US8309068B2 (en) | 2006-08-03 | 2012-11-13 | Myostin Therapeutics Pty Ltd. | Isolated polypeptides and methods of improving muscle strength |
CA2661836A1 (en) * | 2006-09-05 | 2008-03-13 | Eli Lilly And Company | Anti-myostatin antibodies |
AU2007332819A1 (en) | 2006-12-08 | 2008-06-19 | Acceleron Pharma Inc. | Uses of cerberus, coco and derivatives thereof |
US8895016B2 (en) * | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
EA202091230A3 (ru) * | 2006-12-18 | 2021-01-29 | Акселерон Фарма Инк. | Антагонисты активин-actrii и их применения для повышения уровней эритроцитов |
US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
US9526759B2 (en) * | 2007-02-01 | 2016-12-27 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for treating or preventing breast cancer |
TW201940502A (zh) | 2007-02-02 | 2019-10-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
PT2120999E (pt) * | 2007-02-09 | 2012-12-10 | Acceleron Pharma Inc | Antagonista de activina-actriia e usos para promover o crescimento ósseo em doentes de cancro |
TW201718635A (zh) | 2007-03-06 | 2017-06-01 | 安美基公司 | 變異之活動素受體多肽及其用途 |
US8501678B2 (en) | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
WO2009038745A1 (en) | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
EP2315602A4 (en) * | 2008-06-26 | 2011-11-02 | Acceleron Pharma Inc | METHOD OF DOSING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
DK2340031T3 (da) | 2008-08-14 | 2019-07-15 | Acceleron Pharma Inc | Gdf-fanger til anvendelse ved behandling af anæmi |
CR20160443A (es) | 2008-11-26 | 2016-11-08 | Amgen Inc | Variantes de polipéptidos receptores de activina iib y aplicaciones de éstos (divisional) |
EP2387412A4 (en) * | 2009-01-13 | 2013-04-03 | Acceleron Pharma Inc | METHODS FOR INCREASING ADIPONECTIN |
NZ595235A (en) * | 2009-04-27 | 2013-06-28 | Novartis Ag | Compositions and methods for increasing muscle growth |
MX355042B (es) | 2009-06-08 | 2018-04-02 | Acceleon Pharma Inc | Metodos para aumentar adipositos termogenicos. |
EP3805259A1 (en) | 2009-06-12 | 2021-04-14 | Acceleron Pharma Inc. | Truncated actriib-fc fusion proteins |
EP2496247B1 (en) * | 2009-11-03 | 2017-08-23 | Acceleron Pharma, Inc. | Methods for treating fatty liver disease |
ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
WO2012064771A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma, Inc. | Actriia binding agents and uses thereof |
JP6145112B2 (ja) | 2011-12-19 | 2017-06-07 | アムジエン・インコーポレーテツド | 単独でのまたは化学療法と組み合わされた変異アクチビン受容体ポリペプチド、およびその使用 |
RU2667960C2 (ru) | 2012-04-18 | 2018-09-25 | Ногра Фарма Лимитед | Способы лечения диабета и/или улучшения выживания панкреатических островков после трансплантации |
ES2884095T3 (es) | 2012-11-02 | 2021-12-10 | Celgene Corp | Antagonistas de activina-actrii y usos para el tratamiento de trastornos óseos y otros trastornos |
US20150284455A1 (en) * | 2012-11-06 | 2015-10-08 | Scholar Rock, Inc. | Compositions and methods for modulating cell signaling |
AU2014212014A1 (en) | 2013-02-01 | 2015-08-27 | Amgen Inc. | Administration of an anti-activin-A compound to a subject |
JP2016518357A (ja) | 2013-04-08 | 2016-06-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 骨格筋幹細胞を若返らせる方法および組成物 |
SG10201800800YA (en) | 2013-05-06 | 2018-03-28 | Scholar Rock Inc | Compositions and methods for growth factor modulation |
US20160220640A1 (en) | 2013-06-11 | 2016-08-04 | The Brigham And Women's Hospital, Inc. | Methods and compositions for increasing neurogenesis and angiogenesis |
WO2015070076A2 (en) * | 2013-11-08 | 2015-05-14 | President And Fellows Of Harvard College | Methods and compositions for rejuvenating neuromuscular junctions |
US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
CN106795224B (zh) | 2014-06-04 | 2021-05-18 | 阿塞勒隆制药公司 | 用促滤泡素抑制素多肽治疗病症的方法和组合物 |
TN2016000553A1 (en) | 2014-06-13 | 2018-04-04 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
MA41052A (fr) | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
AU2015342936B2 (en) | 2014-11-06 | 2020-10-08 | Scholar Rock, Inc. | Anti-pro/latent-Myostatin antibodies and uses thereof |
EP4233889A3 (en) | 2014-12-03 | 2023-10-11 | Celgene Corporation | Activin-actrii antagonists and uses for treating myelodysplastic syndrome |
EP3274457A4 (en) | 2015-03-26 | 2018-08-08 | Acceleron Pharma Inc. | Follistatin-related fusion proteins and uses thereof |
CA2983440C (en) | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
SI3350220T1 (sl) | 2015-09-15 | 2021-12-31 | Scholar Rock, Inc. | Protitelesa proti pro/latentnemu miostatinu in uporabe le-teh |
EP3949979A1 (en) | 2016-01-06 | 2022-02-09 | President and Fellows of Harvard College | Treatment with gdf11 prevents weight gain, improves glucose tolerance and reduces hepatosteatosis |
JP2019504064A (ja) | 2016-01-08 | 2019-02-14 | スカラー ロック インコーポレイテッドScholar Rock,Inc. | 抗プロ/潜在型ミオスタチン抗体およびその使用方法 |
AU2017230091B2 (en) | 2016-03-10 | 2022-04-07 | Acceleron Pharma Inc. | Activin type 2 receptor binding proteins and uses thereof |
CN105699661A (zh) * | 2016-03-14 | 2016-06-22 | 陈倩 | Smad6在肝癌诊断治疗中的应用 |
RS61090B1 (sr) | 2016-06-13 | 2020-12-31 | Scholar Rock Inc | Upotreba inhibitora miostatina i kombinovane terapije |
US11155611B2 (en) | 2017-01-06 | 2021-10-26 | Scholar Rock, Inc. | Compositions and methods for making and using anti-myostatin antibodies |
CN107267637B (zh) * | 2017-07-25 | 2021-08-24 | 华南农业大学 | 一种鸡肌间脂肪宽度相关的分子标记及其应用 |
CN109540818A (zh) * | 2018-12-21 | 2019-03-29 | 云南农业大学 | 一种基于钙、磷血液生化标记选育武定鸡的方法 |
CN109754858B (zh) * | 2019-01-11 | 2021-09-21 | 余鹏 | 甲氨蝶呤给药方案确定装置、存储介质及设备 |
CA3153062A1 (en) | 2019-09-03 | 2021-03-11 | Novartis Ag | Treatment of liver disease or disorder comprising actrii receptor antagonists |
CN116600824A (zh) | 2020-07-10 | 2023-08-15 | 巴斯德研究所 | Gdf11诊断和治疗焦虑症和抑郁症的用途 |
CN113223607B (zh) * | 2021-05-28 | 2023-10-20 | 北京化工大学 | 采用smiles算法随机批量生成肝素类似物结构坐标的方法 |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5314695A (en) | 1990-11-13 | 1994-05-24 | Corvas International, Inc. | Tissue factor based prothrombin time reagent |
US5885794A (en) | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
US5994618A (en) | 1997-02-05 | 1999-11-30 | Johns Hopkins University School Of Medicine | Growth differentiation factor-8 transgenic mice |
US6465239B1 (en) * | 1993-03-19 | 2002-10-15 | The John Hopkins University School Of Medicine | Growth differentiation factor-8 nucleic acid and polypeptides from aquatic species and non-human transgenic aquatic species |
ES2201076T3 (es) | 1993-03-19 | 2004-03-16 | The Johns Hopkins University School Of Medicine | Factor-8 de diferenciacion del crecimiento. |
US5734039A (en) | 1994-09-15 | 1998-03-31 | Thomas Jefferson University | Antisense oligonucleotides targeting cooperating oncogenes |
AU6274298A (en) | 1997-02-05 | 1998-08-25 | Johns Hopkins University School Of Medicine, The | Growth differentiation factor-8 |
WO1998052038A1 (en) * | 1997-05-16 | 1998-11-19 | The Procter & Gamble Company | The use of a bone morphogenetic protein (bmp) receptor complex for screening |
US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
AU8666398A (en) | 1997-08-01 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Methods to identify growth differentiation factor (gdf) receptors |
WO1999040181A1 (en) * | 1998-02-05 | 1999-08-12 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
US6004937A (en) * | 1998-03-09 | 1999-12-21 | Genetics Institute, Inc. | Use of follistatin to modulate growth and differentiation factor 8 [GDF-8] and bone morphogenic protein 11 [BMP-11] |
AU765214B2 (en) * | 1998-05-06 | 2003-09-11 | Metamorphix International, Inc. | Methods for treating diabetes by inhibiting gdf-8 |
WO2000029570A1 (fr) * | 1998-11-13 | 2000-05-25 | Takeda Chemical Industries, Ltd. | Nouvelle proteine et son utilisation |
MXPA01007366A (es) * | 1999-01-21 | 2002-06-04 | Metamorphix Inc | Inhibidores de factores de crecimiento y diferenciacion y usos de los mismos. |
EP1593689A3 (en) * | 2000-01-18 | 2006-04-05 | Ovita Limited | Myostatin and mimetics thereof |
-
2000
- 2000-07-27 US US09/626,896 patent/US6656475B1/en not_active Expired - Lifetime
-
2001
- 2001-07-26 EP EP01961756A patent/EP1317485B1/en not_active Expired - Lifetime
- 2001-07-26 WO PCT/US2001/023615 patent/WO2002010214A2/en active Application Filing
- 2001-07-26 AT AT01961756T patent/ATE503487T1/de active
- 2001-07-26 MX MXPA03000787A patent/MXPA03000787A/es active IP Right Grant
- 2001-07-26 AU AU8299901A patent/AU8299901A/xx active Pending
- 2001-07-26 ES ES01961756T patent/ES2364126T3/es not_active Expired - Lifetime
- 2001-07-26 PT PT01961756T patent/PT1317485E/pt unknown
- 2001-07-26 AU AU2001282999A patent/AU2001282999B2/en not_active Ceased
- 2001-07-26 PL PL01365792A patent/PL365792A1/xx not_active Application Discontinuation
- 2001-07-26 DE DE60144334T patent/DE60144334D1/de not_active Expired - Lifetime
- 2001-07-26 CA CA2417568A patent/CA2417568C/en not_active Expired - Fee Related
- 2001-07-26 ES ES10183121.2T patent/ES2532406T3/es not_active Expired - Lifetime
- 2001-07-26 NZ NZ523617A patent/NZ523617A/en not_active IP Right Cessation
- 2001-07-26 DK DK01961756.2T patent/DK1317485T3/da active
- 2001-07-26 BR BR0112788-8A patent/BR0112788A/pt not_active IP Right Cessation
- 2001-07-26 CN CNA2008101449332A patent/CN101402955A/zh active Pending
- 2001-07-26 JP JP2002515943A patent/JP5153985B2/ja not_active Expired - Fee Related
- 2001-07-26 IL IL15397501A patent/IL153975A0/xx unknown
- 2001-07-26 CN CNB018149081A patent/CN100422212C/zh not_active Expired - Lifetime
- 2001-07-26 EP EP10183121.2A patent/EP2322199B1/en not_active Expired - Lifetime
- 2001-07-26 NZ NZ535074A patent/NZ535074A/en not_active IP Right Cessation
- 2001-07-27 AR ARP010103595A patent/AR033384A1/es unknown
-
2003
- 2003-01-17 ZA ZA200300480A patent/ZA200300480B/en unknown
-
2009
- 2009-05-18 IL IL198800A patent/IL198800A0/en unknown
-
2012
- 2012-06-29 JP JP2012147832A patent/JP5785525B2/ja not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
PT1317485E (pt) | 2011-07-06 |
JP2004504832A (ja) | 2004-02-19 |
EP1317485B1 (en) | 2011-03-30 |
JP5785525B2 (ja) | 2015-09-30 |
AR033384A1 (es) | 2003-12-17 |
CN101402955A (zh) | 2009-04-08 |
IL153975A0 (en) | 2003-07-31 |
ZA200300480B (en) | 2004-01-27 |
PL365792A1 (en) | 2005-01-10 |
CA2417568A1 (en) | 2002-02-07 |
WO2002010214A3 (en) | 2003-04-03 |
DE60144334D1 (de) | 2011-05-12 |
EP1317485A2 (en) | 2003-06-11 |
ATE503487T1 (de) | 2011-04-15 |
JP5153985B2 (ja) | 2013-02-27 |
AU8299901A (en) | 2002-02-13 |
EP2322199A1 (en) | 2011-05-18 |
EP2322199B1 (en) | 2014-12-10 |
US6656475B1 (en) | 2003-12-02 |
CN1449410A (zh) | 2003-10-15 |
WO2002010214A2 (en) | 2002-02-07 |
MXPA03000787A (es) | 2004-05-21 |
NZ523617A (en) | 2005-05-27 |
NZ535074A (en) | 2005-12-23 |
AU2001282999C1 (en) | 2002-02-13 |
CN100422212C (zh) | 2008-10-01 |
ES2364126T3 (es) | 2011-08-25 |
IL198800A0 (en) | 2010-02-17 |
ES2532406T3 (es) | 2015-03-26 |
CA2417568C (en) | 2014-07-08 |
AU2001282999B2 (en) | 2006-12-14 |
DK1317485T3 (da) | 2011-07-18 |
JP2012235781A (ja) | 2012-12-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0112788A (pt) | Receptores para fatores de diferenciação de crescimento, agonistas e antagonistas dos mesmos e processos de utilização desses | |
BR0209191A (pt) | Uso de folistatina para aumentar a massa muscular | |
BR9811774A (pt) | Tetraidroprostaglandinas aromáticas substituìdas por c16-c20 úteis como agonistas fp | |
BR9811779A (pt) | Tetrahidro prostaglandina s substituìdas por c16-c20 aromáticos úteis como agonistas fp | |
BR0309623A (pt) | Agentes que regulam. inibem ou modulam a atividade e/ou a expressão do fator de crescimento de tecido conjuntivo (ctgf) como um único meio de diminuir a pressão intraocular e tratar retinopatias glaucomatosas/neuropatias ópticas | |
BR0011823A (pt) | Derivado de benzimidazol, composto, composição farmacêutica, uso de um derivado de benzimidazol, e, método para tratamento, prevenção ou alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo animal vivo | |
BR0114754A (pt) | Compostos não-imidazóis | |
ATE330959T1 (de) | Allosterische adenosin-rezeptor-modulatore | |
BR0013667A (pt) | Derivados de glucopiranosiloxipirazol, composições medicinais contendo os mesmos derivados e seus intermediários na produção dos mesmos | |
BR0211284A (pt) | Derivados de 1-fenilsulfonil-1,3-dihidro-2h-indol-2-ona, a respectiva preparação e a respectiva aplicação em terapêutica | |
BR9812631A (pt) | Tetraidro prostaglandinas substituìdas por c16-c20 aromáticos úteis como agonistas de fp | |
BR0212455A (pt) | Composto, formulação farmacêutica, combinação, uso de um composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìfero, e, processo para preparar um composto | |
BR9800524A (pt) | Derivados de 1,3,8-triaza-espiro[4,5]decan-4-ona substituìda na posição 8 | |
BR0115847A (pt) | Compostos especìficos para receptor para adenosina a1, a2a, e a3 e usos dos mesmos | |
JP4675103B2 (ja) | 脳機能を改善する医薬組成物および脳機能を改善するための方法 | |
BR0007229A (pt) | Aminoazaciclos heterocìclicos substituìdos úteis como agentes de sistema nervoso central | |
BRPI0417833A (pt) | novos derivados de benzofurano, os quais podem ser usados na profilaxia ou tratamento de distúrbios relacionados com o receptor 5-ht6 | |
BR0014939A (pt) | Oligossacarìdeos, processo de preparação de oligossacarìdeos, composições farmacêuticas, e, utilização de oligossacarìdeos | |
BRPI0407253A (pt) | Heterociclil-3-sulfonilindazóis como ligandos 5-hidroxitriptamina-6 processo de preparação dos mesmos, seus usos na preparação de uma composição farmacêutica e composição farmacêutica compreendendo os referidos compostos | |
BR9811923A (pt) | Compostos possuindo atividade neuronal | |
AU2101800A (en) | Skin protection agents containing a fragment mixture produced from hyaluronic acid by hydrolysis | |
BR9914158A (pt) | Composição antibiótica para o tratamento dos olhos, ouvidos e nariz | |
BR0316042A (pt) | Kits que contêm compressa para o corpo e dispositivo térmico fixável de modo liberável | |
BR0111933A (pt) | Uso de ácido pamÈico ou um de seus derivados, ou um de seus análogos, para a preparação de um medicamento para o tratamento de doenças caracterizadas por depósitos de agregados amilõides | |
BR0014742A (pt) | Método para a inibição de uma resposta pró-inflamatória de uma célula mononuclear e célula polimorfonuclear de sangue periférico humano, ou uma célula de tecido fixado, quando contactada com um agente pró-inflamatório, complexo de receptor, e, método para a identificação de um agente de modificação de via de sinal de proteìna g quinase |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A E 10A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2112 DE 28/06/2011. |